GlassScriptPhysician profile
Mandhir S Jamwal
NPI 1932302346
$3,868.83
in general payments reported to CMS, 2019-2025
28 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $409 · 2021: $544 · 2022: $268 · 2023: $654 · 2024: $702 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.21 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.70 | 2019-2024 | |
| Lilly USA, LLC | $547.54 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $354.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $242.65 | 2019-2020 | |
| Novo Nordisk INC | $233.06 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.25 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $173.96 | 2022-2023 | Veozah, Myrbetriq |
| Amgen INC. | $165.42 | 2019-2024 | Repatha |
| Pfizer INC. | $162.64 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.59 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $138.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $135.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $117.95 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.68 | 2022-2024 | |
| Mylan Specialty L.P. | $86.10 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.81 | 2019-2020 | |
| Radius Health, INC. | $73.57 | 2019-2023 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $46.76 | 2020 | |
| Amarin Pharma, INC. | $36.65 | 2020 | |
| Sunovion Pharmaceuticals INC. | $33.56 | 2021 | |
| Smith+Nephew, INC. | $27.29 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.36 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.16 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $20.81 | 2023 | Strensiq |
| Allergan, INC. | $13.34 | 2020 | |
| Corcept Therapeutics | $12.59 | 2019 | |
| Glaxosmithkline, LLC. | $11.70 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandhir Jamwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.